Omada Health's virtual physical therapy program shows reduced healthcare costs and utilization for musculoskeletal conditions compared to in-person therapy.
Quiver AI Summary
Omada Health announced findings from a study indicating that its virtual physical therapy program for musculoskeletal (MSK) conditions results in lower medical care utilization and costs compared to traditional in-person physical therapy. This research, which is one of the first peer-reviewed analyses to evaluate both the cost-effectiveness and usage of virtual versus in-person therapy, shows that participants in Omada's program experienced significant savings over six and twelve months, with reported median savings of over $100 per member per month and total savings exceeding $1,000 per member. This is particularly relevant given the rising costs associated with MSK conditions, which represent a major financial burden on the healthcare system. Omada's findings suggest that virtual therapy not only provides effective treatment but can also be more economical, benefiting both patients and employers by reducing overall healthcare costs.
Potential Positives
- Demonstrated lower utilization of total medical care and reduced MSK-related costs for patients using Omada’s virtual physical therapy program compared to in-person therapy, highlighting the effectiveness of the service.
- The study is one of the first to peer-review and analyze the cost-effectiveness of virtual versus in-person physical therapy, providing credibility and supporting the case for the virtual program.
- Median per-member-per-month savings of over $100 within the first six months and over $1,000 at six and twelve months indicates substantial financial benefits, positioning the service favorably for employers and health plans.
- URAC accreditation for Telehealth supports Omada's commitment to quality care in virtual settings, enhancing the company’s reputation in the digital health industry.
Potential Negatives
- The press release focuses heavily on the benefits of virtual physical therapy, leaving unaddressed any potential downsides or disadvantages compared to in-person physical therapy, which may raise concerns about transparency.
- While the new study presents positive outcomes, it does not provide detailed information about the methodology or the sample size, which could lead to questions about the validity and reliability of the findings.
- There is no mention of any regulatory challenges or competitive threats that could impact Omada Health's market position in the growing digital health space, indicating a lack of comprehensive risk assessment in their communication.
FAQ
What is Omada Health's new study about?
Omada Health's study compares virtual physical therapy (V-PT) and in-person physical therapy (IP-PT) for musculoskeletal conditions, highlighting cost savings and reduced healthcare utilization.
How does virtual physical therapy save costs?
The study found that patients using Omada's V-PT program experienced lower medical care utilization and significant cost savings compared to traditional in-person therapy.
What are the key findings from the Omada study?
Omada's study indicated that V-PT resulted in over $100 monthly savings per member and a positive ROI of 1.8x within 12 months.
Why is virtual physical therapy important?
Virtual physical therapy improves access for patients, reduces barriers to care, and can lead to significant savings for individuals and employers dealing with musculoskeletal issues.
Is Omada Health accredited?
Yes, Omada for Joint & Muscle Health has earned URAC accreditation for Telehealth, ensuring high-quality treatment delivered by licensed physical therapists.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OMDA Analyst Ratings
Wall Street analysts have issued reports on $OMDA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 08/08/2025
- Canaccord Genuity issued a "Buy" rating on 08/08/2025
- Barclays issued a "Overweight" rating on 08/08/2025
- Evercore ISI Group issued a "Outperform" rating on 07/09/2025
- JP Morgan issued a "Overweight" rating on 07/01/2025
- Morgan Stanley issued a "Overweight" rating on 07/01/2025
- Goldman Sachs issued a "Buy" rating on 07/01/2025
To track analyst ratings and price targets for $OMDA, check out Quiver Quantitative's $OMDA forecast page.
$OMDA Price Targets
Multiple analysts have issued price targets for $OMDA recently. We have seen 7 analysts offer price targets for $OMDA in the last 6 months, with a median target of $24.0.
Here are some recent targets:
- Saket Kalia from Barclays set a target price of $24.0 on 08/08/2025
- Richard Close from Canaccord Genuity set a target price of $28.0 on 08/08/2025
- Ryan MacDonald from Needham set a target price of $24.0 on 08/08/2025
- An analyst from Evercore ISI Group set a target price of $23.0 on 07/09/2025
- Destiny Jackson from JP Morgan set a target price of $20.0 on 07/01/2025
- Craig Hettenbach from Morgan Stanley set a target price of $25.0 on 07/01/2025
- David Roman from Goldman Sachs set a target price of $29.0 on 07/01/2025
Full Release
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada’s virtual physical therapy (PT) program to address musculoskeletal (MSK) conditions, Omada for Joint & Muscle Health, had lower utilization of total medical care and reduced MSK-related costs and encounters on average at 6 and 12 months compared to patients who used in-person PT (IP-PT). This study is believed to be one of the first peer-reviewed healthcare claims analyses to compare costs and utilization of virtual PT (V-PT) and IP-PT in treating MSK conditions while also accounting for the cost of the virtual program itself.
In the U.S., MSK conditions affect more than one in two adults and cost the healthcare system over $420 billion in 2018—more than cost of diabetes, heart disease, or any other chronic condition.² While physical therapy is often the first line of defense for MSK-related conditions³ ahead of costlier and higher-risk interventions like surgery, patients can face multiple barriers to accessing and participating in timely physical therapist care—geographic barriers, provider availability, and coverage restrictions like coinsurance or limits on the number of visits.⁴ Delays in starting PT treatment can add to downstream costs associated with care—like imaging and pain management—and increase the cost burden on individuals, employers, and health plans alike.⁵
“Previous studies have shown that virtual physical therapy can reduce healthcare utilization and spending, but they have left out critical cost components,” said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. “Our findings demonstrate that Omada’s human-led, virtual MSK program not only reduced direct service expenditures but also has the potential to be more cost-effective than in-person physical therapy over time, even after accounting for the cost of the program itself.”
Omada’s study used Identity Manager, HealthVerity’s patient de-identification and identity resolution technology, and claims data from July 2019 to May 2023, sourced from HealthVerity Marketplace ™, to compare V-PT patients in Omada for Joint & Muscle Health to a control group of patients enrolled in IP-PT to analyze healthcare utilization, cost savings, and return on investment (ROI) at 6 and 12 months post-treatment initiation. As a partner to digital health innovators, HealthVerity works with companies like Omada to validate impact using a large, privacy-protected real-world data ecosystem.
Omada’s virtual MSK program was found to have a significant impact on all measures in the study when compared to controls, yielding a lower utilization of total medical care, driven in large part by a reduction in MSK-related costs and encounters. Median per-member-per-month savings were more than $100 in the first six months, with median gross MSK savings per member over $1,000 at both six and 12 months, reflecting a positive ROI (1.8x) at both six and 12 months.¹
These savings are significant as research has shown that employers spend $353 billion annually on MSK-related treatments and conditions for their employees,⁶ which accounts for nearly 15% of their total medical costs.
“For employers and health plans, this study is a significant indicator of the value of virtual MSK programs with meaningful ROI in just the first year,” said Wei-Li Shao, President, Omada Health. “Given that those with chronic MSK pain have been found to be almost twice as likely as those without to have cardiovascular disease,⁶ we are well-positioned as a virtual-first, cardiometabolic care provider to provide high-quality MSK care to employers and payers who are consistently looking for ways to consolidate their offerings.”
Omada for Joint & Muscle Health has earned URAC for Telehealth accreditation, and provides treatments delivered by extensively trained, licensed physical therapists.
“We’re proud to contribute to Omada’s growing body of peer-reviewed studies and to the broader industry literature, leveraging claims data to demonstrate the potential for virtual care programs, like Omada for Joint & Muscle Health, to deliver care that can be more cost-effective than traditional, in-person PT,” said Ian Livingstone, Senior Director, Data Insights & Analytics, HealthVerity. “These findings highlight how real-world data can uncover the true impact of digital interventions on both patient outcomes and value-based care.”
Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.
The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work ® . An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.
Contacts
Rose Ramseth
[email protected]
Sources
- Napoleone, JM, Devaraj, SM, Noble, M, et al. Health Care Cost Savings and Utilization Reductions Associated With Virtual Physical Therapy Care: A Propensity-Matched Claims Analysis. Phys Ther. 2025;105(8). https://doi.org/10.1093/ptj/pzaf084
- The health care total cost of musculoskeletal conditions. Evernorth. August 3, 2022. Accessed July 22, 2025. https://www.evernorth.com/articles/health-care-total-cost-musculoskeletal-conditions.
- Lin I, Wiles L, Waller R, et al. What does best practice care for musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical practice guidelines: systematic review. British Journal of Sports Medicine. 2020;54:79-86.
- Carvalho E, Bettger JP, Goode AP. Insurance Coverage, Costs, and Barriers to Care for Outpatient Musculoskeletal Therapy and Rehabilitation Services. N C Med J. 2017 Sep-Oct;78(5):312-314. doi: 10.18043/ncm.78.5.312. PMID: 28963265; PMCID: PMC6021174.
- Addressing Musculoskeletal Conditions and Physical Therapy Needs with Virtual Solutions: Key Trends and Employer Considerations. Business Group on Health. November 15, 2024. Accessed July 22, 2025. https://www.businessgrouphealth.org/resources/addressing-musculoskeletal-conditions-and-physical-therapy-needs-with-virtual-solutions .
- Oliveira CB, Maher CG, Franco MR, Kamper SJ, Williams CM, Silva FG, Pinto RZ. Co-occurrence of Chronic Musculoskeletal Pain and Cardiovascular Diseases: A Systematic Review with Meta-analysis. Pain Med. 2020 Jun 1;21(6):1106-1121. doi: 10.1093/pm/pnz217. PMID: 31591645.